SOCS3 / Suppressor of cytokine signaling 3 · IHC design guide

Design Immunohistochemistry for SOCS3

Plan chromogenic SOCS3 IHC on paraffin sections using the catalog antibody's 0.5–1 μg/ml range (datasheet PA1707). Compare cytoplasmic staining in high-staining fallopian tube non-ciliated cells or gallbladder glandular cells with adipocytes where staining was not detected (HPA tissue IHC).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for SOCS3 (IHC for SOCS3): expected localisation Cytoplasmic staining in most tissues (HPA tissue IHC), antibody PA1707, validated IHC image, and IHC protocol steps — Printable **SOCS3** IHC protocol sheet — expected localisation Cytoplasmic staining in most tissues (HPA tissue IHC), antibody PA1707, controls and protocol steps. Open the full SOCS3 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

SOCS3 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasmic staining in most tissues (HPA tissue IHC)
	Staining pattern	Mostly cytoplasmic; high in fallopian tube non-ciliated cells (HPA tissue IHC)
	Antigen retrieval	Citrate pH 6 HIER, heat-mediated (datasheet PA1707)
	Positive control ⓘ	Fallopian tube+4 more · see all
	Negative control ⓘ	Adipose tissue+4 more · see all

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent across sections. (standard IHC practice; not target-specific)
	Caveat	Adipose RNA enrichment may not predict adipocyte staining (HPA tissue IHC; HPA RNA)
	Regulation	Cytokine-responsive expression (UniProt)
	Isoform / epitope	One 1–225 chain; no isoforms or processing annotated (UniProt)

Section 1

Recommended SOCS3 IHC & IF Protocols

Compare the catalog antibody’s IHC-P protocol (datasheet PA1707) with four published SOCS3 chromogenic IHC protocols (PMC3070874; PMC7474768; PMC3445460; PMC7391185).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded human tonsil tissues; fixative not specified (datasheet PA1707)
Fixation	Image fixative and duration unreported (datasheet PA1707); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: Citrate pH 6, 20 min (datasheet PA1707)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% goat serum (datasheet PA1707)
Primary antibody	Rabbit anti-SOCS3, 0.5-1μg/ml (datasheet PA1707)
Primary incubation	Overnight at 4 °C (datasheet PA1707)
Detection	Streptavidin-biotin complex (SABC), DAB chromogen (datasheet PA1707)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	SOCS3-positive staining in non-ciliated cells of fallopian tube (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in most tissues. No signal in the no-primary control.

💡Decision noteStart with citrate pH 6 heat retrieval (datasheet PA1707); evaluate high-pH retrieval if needed for the tissue, as reported for human sections (PMC3070874).

Section 2

What Is the Expected SOCS3 Staining Pattern?

SOCS3 staining in paraffin IHC is predominantly cytoplasmic across many tissues (HPA: tissue IHC profile, Approved; pending external verification). Expect the strongest listed staining in fallopian tube non-ciliated cells and gallbladder glandular cells (HPA: High in both). SOCS3 has no transmembrane segment or signal peptide (UniProt O14543 topology and processing). HPA separately reports cytosol as the main ICC-IF location, with additional plasma membrane localisation (HPA: subcellular ICC-IF).

What am I looking at on my slide?
Clear cytoplasmic staining in fallopian tube non-ciliated cells or gallbladder glandular cells.	This matches the listed high-intensity cell populations (HPA: High in both). Compare the named cells with nearby cells on the same section; whole-tissue colour alone cannot establish the expected cell pattern (general IHC practice).
Predominantly nuclear staining, with little cytoplasmic signal.	This differs from the reported tissue IHC pattern (HPA: cytoplasmic expression in most tissues). Check morphology, counterstain and detection controls before calling it SOCS3; UniProt provides no subcellular annotation to justify a nuclear call (UniProt O14543).
Strong colour in a cell population listed as undetected, such as prostate glandular cells.	This conflicts with that HPA observation (HPA: Not detected in prostate glandular cells). Consider off-target binding or endogenous chromogen-generating activity, then compare a negative control and another cell population; one discordant section alone does not establish the cause (general IHC practice).
Haze, colour over broad tissue areas, or staining that ignores cell boundaries.	A diffuse deposit is harder to reconcile with cell-resolved cytoplasmic staining (HPA: tissue IHC profile). Review background in a primary-antibody omission control and inspect wash, blocking and chromogen conditions (general IHC practice).
No visible signal in the expected cells of a high-staining reference section.	First confirm that fallopian tube non-ciliated or gallbladder glandular cells are present and intact (HPA: High in both). Then check the IHC-validated antibody and detection controls; a single blank section cannot distinguish low target signal from a failed assay (general IHC practice).

💡Expected SOCS3 appearanceCall a positive result when identifiable fallopian tube non-ciliated or gallbladder glandular cells show clear, predominantly cytoplasmic staining, potentially strong in those listed populations (HPA: High; cytoplasmic tissue profile); widespread nuclear colour or diffuse cell-independent deposit warrants control review (general IHC practice).

How each factor affects the staining
Cell identity and tissue choice	The high examples are specific cell populations, not blanket claims about every cell in those organs (HPA: High in fallopian tube non-ciliated cells and gallbladder glandular cells). Adrenal glandular, bone marrow hematopoietic and bronchial basal cells are listed at medium intensity (HPA: Medium).
Interpretation of low or absent staining	HPA lists low staining in lung alveolar cells and liver cholangiocytes, while adipocytes in adipose tissue and breast are not detected (HPA: tissue IHC). These entries apply to the named cell types; they do not define universal negative tissues or assay failure thresholds.
RNA versus protein readout	Adipose tissue has tissue-enhanced RNA specificity, yet adipocytes in the listed tissue IHC entries are not detected (HPA: RNA specificity; tissue IHC). Choose IHC comparison cells from the protein staining observations rather than inferring adipocyte staining from RNA enrichment.
Protein form and topology	The annotated chain spans residues 1–225, with no signal peptide, propeptide or transmembrane segment (UniProt O14543 processing and topology). These annotations give no basis to expect a secreted deposit or a membrane-spanning staining pattern in paraffin sections.
Antibody validation scope	The listed tissue IHC antibody CAB012220 is Approved; the HPA tissue profile is also Approved but pending external verification (HPA: antibody validation; tissue reliability). Approved supports use of the reported pattern as a comparison, without proving every positive or negative call in a new specimen.
IF/ICC Q: What location should fluorescence show?	A: Mainly cytosol, with additional plasma membrane localisation (HPA: subcellular ICC-IF, Approved). The listed ICC-IF antibody HPA068569 is Approved for ICC, while its IHC status is unlisted (HPA: antibody validation); interpret the fluorescence observation within its own application.

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
High-staining reference cells are blank.	The expected cells may be absent, or the IHC and detection workflow may have failed (HPA: High in the named reference cells; general IHC practice).	Verify cell identity on the section, then review antibody application, reagent activity and a known-working IHC control (general IHC practice).
Only nuclei appear positive.	The pattern departs from the predominantly cytoplasmic tissue observation (HPA: tissue IHC profile); counterstain or nonspecific detection may complicate interpretation (general IHC practice).	Inspect the primary-antibody omission control and compare nuclear colour with the counterstain before scoring (general IHC practice).
Chromogen appears in cell types listed as undetected.	For example, prostate glandular cells are listed as not detected (HPA: tissue IHC). Off-target antibody signal or endogenous detection activity are possible explanations (general IHC practice).	Check a primary-antibody omission control and an appropriate endogenous-activity control, then compare with the expected cytoplasmic pattern in reference cells (general IHC practice; HPA: tissue profile).
Background is broad and obscures cell outlines.	Excess nonspecific binding, incomplete washing or overdeveloped chromogen can produce diffuse colour (general IHC practice).	Compare the omission control; adjust blocking, washing or chromogen development according to the validated IHC workflow (general IHC practice).
A low-staining population appears negative.	The named population may have little detectable protein: lung alveolar cells and liver cholangiocytes are listed Low (HPA: tissue IHC).	Use the high-staining named cells as a comparison before treating a low-population negative as technical failure (HPA: High in fallopian tube non-ciliated and gallbladder glandular cells).
Adipocyte staining is expected from the RNA result.	The RNA and IHC entries differ: adipose tissue is RNA tissue-enhanced, while adipocytes are not detected in the listed tissue IHC observations (HPA: RNA specificity; tissue IHC).	Score the protein pattern against cell-specific IHC observations and document the RNA–protein difference without assigning a technical cause (HPA: tissue IHC and RNA specificity).

Source: UniProt O14543 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing SOCS3 staining

IHC analysis of SOCS3 using anti-SOCS3 antibody (PA1707). SOCS3 was detected in paraffin-embedded section of human tonsil tissues. Heat mediated antigen retrieval was performed in citrate buffer (pH6, epitope retrieval solution) for 20 mins. The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1μg/ml rabbit anti-SOCS3 Antibody (PA1707) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC)(Catalog # SA1022) with DAB as the chromogen.

PA1707 · IHCIHC analysis of SOCS3 using anti-SOCS3 antibody (PA1707). SOCS3 was detected in paraffin-embedded section of human tonsil tissues. Heat medi

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000184557-SOCS3/tissue/cerebral+cortex#imid_3707824

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000184557-SOCS3/tissue/colon#imid_3707734

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000184557-SOCS3/tissue/liver#imid_3707743

HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000184557-SOCS3/tissue/kidney#imid_3707736

HPA ICC-IF ASC52telo — SOCS3 (HPA068569)

HPA · ICC-IF ASC52teloHuman Protein Atlas immunofluorescence, ASC52telo, antibody HPA068569; green = SOCS3, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for SOCS3 IHC & IF

🧪Run fallopian tube first; its non-ciliated cells should stain for SOCS3 (HPA: High in fallopian tube non-ciliated cells). Use adipose tissue as the negative tissue, with adipocytes at background (HPA: Not detected in adipose adipocytes); on the positive slide, use unstained neighboring cells to assess background, without assigning a specific internal negative cell type that the HPA row does not identify.

Positive control tissue: Fallopian tube (Non-ciliated cells, HPA High)

Negative control tissue: Adipose tissue (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show SOCS3 in ASC52telo, BJ [Human fibroblast], U2OS, with annotated localisation: Cytosol (approved) (HPA subcellular).

Technical controls: Include no-primary (secondary-only) and host-matched rabbit IgG isotype controls, alongside a SOCS3 knockout sample or validated peptide-block control (caption: rabbit anti-SOCS3 antibody; standard IHC practice). For the caption’s biotin-based DAB detection, block or assess endogenous peroxidase and biotin in the fallopian tube section (caption: biotinylated secondary, SABC and DAB; standard IHC practice).

⚠️Feasibility: The selected PA1707 paraffin-section caption reports citrate retrieval at pH 6 for 20 minutes in tonsil, but gives no fixative; a target-specific fixation window and retrieval requirement for fallopian tube are unreported (caption: PA1707 tonsil IHC). Frozen-section feasibility is unreported, and the available ICC-IF images establish cell imaging rather than easier tissue IF (HPA: ICC-IF images in ASC52telo, BJ and U2OS). No fallopian tube-specific artifact is reported in the supplied evidence; assess background from the biotin-based DAB method on the chosen tissue (caption: SABC and DAB; standard IHC practice).

HPA tissue IHC evidence for SOCS3

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Fallopian tube	Non-ciliated cells	High	Protein (IHC)	HPA →
Gallbladder	Glandular cells	High	Protein (IHC)	HPA →
Adrenal gland	Glandular cells	Medium	Protein (IHC)	HPA →
Bone marrow	Hematopoietic cells	Medium	Protein (IHC)	HPA →
Bronchus	Basal cells	Medium	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Adipose tissue	Adipocytes	Not detected	Protein (IHC)	HPA →
Breast	Adipocytes	Not detected	Protein (IHC)	HPA →
Lymph node	Germinal center cells	Not detected	Protein (IHC)	HPA →
Prostate	Glandular cells	Not detected	Protein (IHC)	HPA →
Smooth muscle	Smooth muscle cells	Not detected	Protein (IHC)	HPA →

Section 3

Advanced SOCS3 IHC Tips

Troubleshoot SOCS3 staining in paraffin sections by checking retrieval, controls, cellular localisation and scoring before interpreting changes in chromogenic signal.

What retrieval conditions should I try when SOCS3 staining is weak in paraffin sections?

Start with heat-mediated retrieval in citrate buffer at pH 6 for 20 minutes (datasheet PA1707). The documented paraffin-section example then used 10% goat serum blocking and 1 µg/ml primary antibody overnight at 4°C (datasheet PA1707). If staining remains weak, compare a different retrieval buffer or pH on adjacent sections while holding detection and development constant (standard IHC practice). Include a positive reference section in each run so that weak signal can be distinguished from a failed retrieval or detection step (standard IHC practice). Do not treat retrieval-dependent signal alone as proof of SOCS3 specificity (standard IHC practice).

Could fixation explain weak or patchy SOCS3 staining in my paraffin sections?

Target-specific sensitivity of SOCS3 staining to fixative type or fixation time is unknown from the supplied evidence (datasheet PA1707: fixative not stated). The documented image shows paraffin-embedded human tonsil, but its caption does not identify the fixative or establish an optimal fixation schedule (datasheet PA1707). For a practical comparison, process matched samples with recorded fixation conditions, then apply the same pH 6 citrate retrieval and detection workflow (datasheet PA1707; standard IHC practice). Compare tissue morphology and SOCS3 signal against a reference section stained in the same run, keeping section thickness and development time consistent (standard IHC practice).

How should I assess cytoplasmic and membrane-associated SOCS3 staining?

Assess the cytoplasmic compartment first: tissue IHC describes cytoplasmic expression in most tissues, and cell imaging places SOCS3 mainly in the cytosol (HPA tissue IHC; HPA subcellular). Additional plasma-membrane localisation is reported in cell imaging, so a peripheral signal can be plausible when cellular borders are resolved (HPA subcellular). SOCS3 has no transmembrane segment; membrane-adjacent staining should therefore be described as localisation, not evidence that SOCS3 spans the membrane (UniProt O14543 topology; HPA subcellular). Score cytoplasmic and peripheral patterns separately, and compare each with background in a matched negative-control section (standard IHC practice).

How do SOCS3 domains affect interpretation when an antibody epitope is unspecified?

The record lists one chain spanning residues 1–225 and no annotated isoforms, so an additional staining pattern should not be assigned to a documented SOCS3 isoform (UniProt O14543 processing and isoforms). SOCS3 contains an SH2 domain at residues 46–142 and a SOCS box at 177–224 (UniProt O14543 domains). Those positions do not identify where this antibody binds, because the supplied caption gives no epitope sequence (datasheet PA1707). If a staining pattern changes with retrieval, compare serial sections and an independent specificity control before attributing the change to epitope exposure (standard IHC practice).

How can I check SOCS3 localisation with multiplex IF alongside chromogenic IHC?

Pair SOCS3 with a marker for the expected cell population, such as glandular cells in gallbladder, and assess overlap cell by cell (HPA tissue IHC: high in gallbladder glandular cells; standard IF practice). Choose a fluorophore channel with low tissue autofluorescence and inspect unstained and single-stained controls before interpreting colocalisation (standard IF practice). Because SOCS3 is mainly cytosolic with additional plasma-membrane localisation, use permeabilisation when testing an intracellular epitope, while recognising that this antibody’s epitope is unspecified (HPA subcellular; datasheet PA1707; standard IF practice). Optimise IF antibody concentration independently; the documented 1 µg/ml concentration applies to paraffin-section IHC (datasheet PA1707).

What should I check when SOCS3 DAB staining appears diffuse or widespread?

The documented paraffin-section workflow uses a biotinylated secondary antibody, a streptavidin–biotin detection complex and DAB, so check each detection stage when diffuse colour appears (datasheet PA1707). Run a primary-omission control and apply a peroxidase block to assess detection-related staining; peroxidase blocking is a general chromogenic IHC step (standard IHC practice). Keep retrieval, the documented 10% goat serum block and DAB development consistent while adjusting primary antibody exposure on adjacent sections (datasheet PA1707; standard IHC practice). Compare candidate signal with tissue architecture and cytoplasmic localisation rather than counting uniform extracellular colour as SOCS3-positive cells (HPA tissue IHC; standard IHC practice).

How should I quantify SOCS3 staining across sections with different cell composition? ⚠ ANSWER MARKED FOR VERIFICATION

Define the cell population and compartment before scoring: HPA reports high SOCS3 staining in fallopian-tube non-ciliated cells and gallbladder glandular cells, whereas several other populations are not detected (HPA tissue IHC). For chromogenic sections, record percent positive cells and intensity on a 0–3 scale, then calculate an H-score from 0–300 (standard IHC practice). Normalise cell-based results to the number of evaluable cells in the same compartment, or report positive-cell density per mm² of viable tissue (standard IHC practice). Use identical thresholds, counterstain settings and region-selection rules across sections, and exclude folds and necrotic regions from scored area (standard IHC practice).

How can I distinguish credible SOCS3 staining from tissue or detection artefact?

A credible pattern is predominantly cytoplasmic in the relevant cell population; membrane-adjacent signal may occur, but a purely extracellular pattern conflicts with the reported cellular localisation (HPA tissue IHC; HPA subcellular). Check whether the stained cells match the section’s known pattern, such as high staining in gallbladder glandular cells versus no detected staining in prostate glandular cells (HPA tissue IHC). Discount staining confined to section edges, folds or necrotic areas, and compare it with a primary-omission control for endogenous enzyme or detection signal (standard IHC practice). Interpret apparent biological changes cautiously because SOCS3 participates in cytokine-signalling negative feedback and IHC intensity alone does not establish pathway activity (UniProt O14543 function; standard IHC practice).

Boster reagents

Best SOCS3 / Suppressor of cytokine signaling 3 IHC Antibodies

PA1707 has real SOCS3 IHC data from paraffin-embedded human tonsil (PA1707 image caption). Its listed reactivity covers human and mouse (catalog reactivity).

Real IHC data

Anti-SOCS3 Antibody ®

Cat # PA1707

View product →

PA1707 is listed for IHC and shows SOCS3 staining in a paraffin-embedded human tonsil section (catalog applications; PA1707 image caption). Mouse reactivity is listed, but the supplied IHC image shows human tissue only (catalog reactivity; PA1707 image caption).

Which to pick: For tissue IHC, choose PA1707: its rabbit antibody was used on paraffin-embedded human tonsil with citrate pH 6 retrieval and 1 μg/ml primary antibody (PA1707 image caption). No IF/ICC choice is supported by this payload because PA1707 has no listed IF application or IF image (catalog applications; catalog IF images). For cross-species planning, PA1707 lists human and mouse reactivity; its IHC caption reports no fixative (catalog reactivity; PA1707 image caption).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry O14543 (SOCS3_HUMAN, Suppressor of cytokine signaling 3).
Human Protein Atlas. SOCS3 tissue IHC expression (reliability: Approved).
Human Protein Atlas. SOCS3 subcellular location (ICC-IF): Mainly localized to the cytosol. In addition localized to the plasma membrane..
Human Protein Atlas. SOCS3 antibody validation summary (2 antibodies).
Suppressor of cytokine signalling protein SOCS3 expression is increased at sites of acute and chronic inflammation. Journal of molecular histology 2011 — PMC3070874.
Effect of Total Flavonoids of Oxytropis falcata Bunge on the Expression of p-JAK1-and p-STAT1-Related Proteins in Idiopathic Pulmonary Fibrosis. Evidence-based complementary and alternative medicine : eCAM 2020 — PMC7474768.
Loss of expression and function of SOCS3 is an early event in HNSCC: altered subcellular localization as a possible mechanism involved in proliferation, migration and invasion. PloS one 2012 — PMC3445460.
Correlation of PD-L1 and SOCS3 Co-expression with the Prognosis of Hepatocellular Carcinoma Patients. Journal of Cancer 2020 — PMC7391185.
PubMed PMID:9266833 — UniProt-cited evidence.
PubMed PMID:9344848 — UniProt-cited evidence.
PubMed PMID:11071852 — UniProt-cited evidence.